Diclofenac Sodium 4% Spray Gel - cyathus.cz
Diclofenac Sodium 4% Spray Gel - cyathus.cz
Diclofenac Sodium 4% Spray Gel - cyathus.cz
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
PAR <strong>Diclofenac</strong> <strong>Sodium</strong> <strong>4%</strong> <strong>Spray</strong> <strong>Gel</strong><br />
UK/H/0562-3/001/E01<br />
<strong>Diclofenac</strong> <strong>Sodium</strong> <strong>4%</strong> <strong>Spray</strong> <strong>Gel</strong><br />
LAY SUMMARY<br />
Czech Republic, Poland, Slovak Republic, Estonia, Hungary, Latvia, Lithuania,<br />
Slovenia today granted Mika Pharma GmbH Marketing Authorisations (licences) for<br />
the medicinal products <strong>Diclofenac</strong> <strong>Sodium</strong> <strong>4%</strong> <strong>Spray</strong> <strong>Gel</strong> (PL 18017/0001-2). These<br />
are prescription only medicines (POM) for the relief of acute pain and swelling<br />
affecting small or medium-sized joints and surrounding tissues.<br />
<strong>Diclofenac</strong> <strong>Sodium</strong> <strong>4%</strong> <strong>Spray</strong> <strong>Gel</strong> contain the active ingredient diclofenac sodium,<br />
which belongs to a group of drugs called non-steroidal anti-inflammatory drugs<br />
(NSAID).<br />
No new or unexpected safety concerns arose from these applications and it was<br />
therefore judged that the benefits of taking <strong>Diclofenac</strong> <strong>Sodium</strong> <strong>4%</strong> <strong>Spray</strong> <strong>Gel</strong><br />
outweigh the risks, hence Marketing Authorisations have been granted.<br />
2
Change language